RAP1A and melanoma: To further investigate the potential role of targeted therapy by inhibiting the cholesterol-27HC-Rap1 axis in vemurafenib-resistant melanoma, a vemurafenib-resistant A375 cell line (A375-VR) was established by continuous treatment with vemurafenib for weeks.